Roy Bannister
Overview
Explore the profile of Roy Bannister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woolsey C, Cross R, Chu V, Prasad A, Agans K, Borisevich V, et al.
Sci Adv
. 2025 Mar;
11(11):eadw0659.
PMID: 40085692
Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV...
2.
Cross R, Woolsey C, Prasad A, Borisevich V, Agans K, Deer D, et al.
Nat Med
. 2025 Jan;
PMID: 39805309
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or...
3.
Zumbrun E, Garvey C, Wells J, Lynn G, Van Tongeren S, Steffens J, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772240
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here,...
4.
Martinez D, Moreira F, Catanzaro N, Diefenbacher M, Zweigart M, Gully K, et al.
Sci Transl Med
. 2024 May;
16(748):eadj4504.
PMID: 38776389
Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that...
5.
Cross R, Woolsey C, Chu V, Babusis D, Bannister R, Vermillion M, et al.
Science
. 2024 Mar;
383(6688):eadk6176.
PMID: 38484056
Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show...
6.
Zumbrun E, Garvey C, Wells J, Lynn G, Van Tongeren S, Steffens J, et al.
Viruses
. 2023 Dec;
15(12).
PMID: 38140576
Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The...
7.
Martinez D, Moreira F, Zweigart M, Gully K, De la Cruz G, Brown A, et al.
bioRxiv
. 2023 Jul;
PMID: 37425890
Despite the wide availability of several safe and effective vaccines that can prevent severe COVID-19 disease, the emergence of SARS-CoV-2 variants of concern (VOC) that can partially evade vaccine immunity...
8.
Peart Akindele N, Katamoni L, Brockhurst J, Ghimire S, Suwanmanee S, Pieterse L, et al.
Sci Rep
. 2023 Apr;
13(1):6463.
PMID: 37081035
Measles is a systemic disease initiated in the respiratory tract with widespread measles virus (MeV) infection of lymphoid tissue. Mortality can be substantial, but no licensed antiviral therapy is available....
9.
Pitts J, Babusis D, Vermillion M, Subramanian R, Barrett K, Lye D, et al.
Antiviral Res
. 2022 May;
203:105329.
PMID: 35525335
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir (RDV, VEKLURY®) is currently...
10.
Schafer A, Martinez D, Won J, Meganck R, Moreira F, Brown A, et al.
Sci Transl Med
. 2022 Mar;
14(643):eabm3410.
PMID: 35315683
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, underscoring the need to develop highly...